Related references
Note: Only part of the references are listed.Guidelines for experimental models of myocardial ischemia and infarction
Merry L. Lindsey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2018)
Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection
Hans Erik Botker et al.
BASIC RESEARCH IN CARDIOLOGY (2018)
The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR) A New Paradigm for Rigorous, Accurate, and Reproducible Evaluation of Putative Infarct-Sparing Interventions in Mice, Rabbits, and Pigs
Steven P. Jones et al.
CIRCULATION RESEARCH (2015)
Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice
Yiru Guo et al.
BASIC RESEARCH IN CARDIOLOGY (2012)
The COX-2/PGI2 Receptor Axis Plays an Obligatory Role in Mediating the Cardioprotection Conferred by the Late Phase of Ischemic Preconditioning
Yiru Guo et al.
PLOS ONE (2012)
Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences
Qianhong Li et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models
Qianhong Li et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences
Qianhong Li et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
The Second Window of Preconditioning (SWOP) Where Are We Now?
Derek J. Hausenloy et al.
CARDIOVASCULAR DRUGS AND THERAPY (2010)
Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection
Javier Inserte et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function
B Dawn et al.
CIRCULATION RESEARCH (2006)
Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
A Abbate et al.
HEART (2004)
Mechanism of cyclooxygenase-2 upregulation in late preconditioning
YT Xuan et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2003)
Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism
QH Li et al.
CIRCULATION RESEARCH (2003)
Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter
A Sanbe et al.
CIRCULATION RESEARCH (2003)
Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits
K Shinmura et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning
R Bolli et al.
CARDIOVASCULAR RESEARCH (2002)
Involvement of endogenous prostaglandins in ischemic preconditioning in pigs
P Gres et al.
CARDIOVASCULAR RESEARCH (2002)
Prostaglandin E2 induces caspase-dependent apoptosis in rat cortical cells
T Takadera et al.
NEUROSCIENCE LETTERS (2002)
PKCε modulates NF-κB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes
RCX Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2000)
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits
K Shinmura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)